Skip to main content

Table 4 Univariate and multivariate analysis of ZNF331 methylation status with disease-free survival (DFS) and overall survival (OS) in colorectal cancer patients

From: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth

Clinical parameter DFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (< 60 vs. ≥ 60 years) 1.099 (0.604–1.999) 0.757    1.132 (0.622–2.058) 0.685   
Gender (male vs female) 1.129 (0.603–2.114) 0.704    1.080 (0.577–2.023) 0.810   
ZNF331 (methylation vs. unmethylation) 0.273 (0.115–0.648) 0.003** 0.279 (0.117–0.664) 0.004** 0.261 (0.110–0.620) 0.002** 0.271 (0.114–0.646) 0.003**
Tumor differentiation (moderate or well vs. poor) 0.467 (0.254–0.857) 0.014* 0.727 (0.392–1.347) 0.311 0.471 (0.257–0.863) 0.015* 0.736 (0.397–01.365) 0.331
TNM stage (I–II vs. III–IV) 0.139 (0.062–0.312) 0.000*** 0.151 (0.066–0.345) 0.000*** 0.147 (0.065–0.332) 0.000*** 0.164 (0.072–0.375) 0.000***
Tumor size (< 5 vs. ≥ 5 cm) 0.798 (0.438–1.453) 0.461    0.812 (0.446–1.478) 0.495   
Tumor location (left colon vs. right colon) 1.577 (0.810–3.072) 0.180    1.579 (0.811–3.075) 0.179   
KRAS mutation (wide type vs. mutation) 0.797 (0.418–1.520) 0.491    0.810 (0.425–1.545) 0.522   
BRAF 600E mutation (wide type vs. mutation) 0.488 (0.118–2.025) 0.323    0.396 (0.095–1.642) 0.202   
CIMP (high vs. low) 1.155 (0.412–3.242) 0.784    1.138 (0.405–3.192) 0.806   
  1. *p < 0.05, **p < 0.01, ***p < 0.001